Literature DB >> 1490354

Circulating peripheral blood plasma cells in multiple myeloma.

T E Witzig1, R A Kyle, P R Greipp.   

Abstract

These studies indicate that monoclonal plasma cells can be detected in the peripheral blood of patients with active myeloma even when they are not detectable by routine WBC differentials performed on Wright-stained blood smears. These cells are usually not present in patients with MGUS and true SMM. They are detected in approximately 60% of patients with new, active MM and over 90% of patients with relapsed or refractory MM. If treatment is effective, they tend to decrease or disappear from the blood. When immunological, molecular, or cytogenetic studies are performed on peripheral blood cells from patients with MM, it must be realized that monoclonal plasma cells may be present and that they can influence the results of these tests. Although monoclonal plasma cells can circulate in the peripheral blood, it is not yet clear whether this cell represents the myeloma stem cell. It is possible that there are precursor cells that do not have plasma cell morphology in the blood or marrow that then differentiate into plasma cells. This question can only be answered by first depleting the plasma cells and then examining the remaining B-cells with appropriate immunological and molecular techniques.

Entities:  

Mesh:

Year:  1992        PMID: 1490354     DOI: 10.1007/978-3-642-77633-5_23

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  3 in total

1.  Detection of clonal immunoglobulin gene rearrangements in the peripheral blood progenitor cells of patients with multiple myeloma: the potential role of purging with CD34 positive selection.

Authors:  R G Owen; A P Haynes; P A Evans; R J Johnson; A C Rawstron; G McQuaker; G M Smith; M C Galvin; D L Barnard; N H Russell; J A Child; G J Morgan
Journal:  Clin Mol Pathol       Date:  1996-04

Review 2.  Molecular Impact of the Tumor Microenvironment on Multiple Myeloma Dissemination and Extramedullary Disease.

Authors:  Stefan Forster; Ramin Radpour
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

3.  High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma.

Authors:  G Bianchi; R A Kyle; D R Larson; T E Witzig; S Kumar; A Dispenzieri; W G Morice; S V Rajkumar
Journal:  Leukemia       Date:  2012-08-20       Impact factor: 11.528

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.